Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cougar Biotechnology has been enrolled in an open label, dose escalating Phase I trial of the company's drug candidate noscapine, an orally active inhibitor of microtubule dynamics.
Subscribe to our email newsletter
The Phase I trial will evaluate the safety and efficacy of CB3304 (noscapine) administered daily to patients with relapsed or refractory multiple myeloma. The trial will be conducted at Weill Cornell Medical College and Columbia Presbyterian Medical Center.
Alan Auerbach, CEO and president of Cougar Biotechnology, said: “We are pleased to be able to move CB3304 into clinical development. This represents the second drug in Cougar’s pipeline to advance into clinical trials and also represents a key corporate objective for the Company this year.”